Panion at EMA's SME InfoDay

Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.

The SME-office provides an amazing amount of support to foster innovation from academia and small research companies and to help the new ideas from "lab-bench to market". Besides guidance in the complex regulatory field, which is caused by the innovative nature of the new development products, the day also revealed changes in the structures of scientific advice and financial opportunities provided by the European Commission and their support programs.

When a company plans their evidence-creating clinical trials, it is possible to get input and advice to ensure that e.g. the parameters measured in the trial are those found most relevant by the authorities. This was demonstrated to clearly improve the probability for a positive outcome of the marketing authorization application and, hence, a product on the market. 

"Panion plans to pursue all the advice we can get that will help us through with our innovative development product for epilepsy in dogs" says Anja Holm.

The InfoDay provided an overview of EU initiatives supporting development stage SMEs. The future EU funding opportunities were highlighted and platforms for early dialogue with regulators from EMA, national authorities and the EU Innovation Network were presented. Specific support to optimize development plans was described together with feedback on experience at stage of marketing authorization. The event was attended by 120 persons from SME companies and 150 more were linked in via webcast, the majority from the human medicines sector.

FRI, NOV 24, 2017

Anja E. H. Holm, CEO
+ 45-22 94 66 00

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet. 
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases. 


Period October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -854 (-643).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -4 200 (-692).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.


Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.


Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.


Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.



Press releases and reports via E-mail.